REGENXBIO to Host Conference Call on March 7 to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Feb. 28, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV^® Technology Platform, today announced that it will host a conference call on Tuesday, March 7, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2016 and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 77596619. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

About REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV^® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform Licensees. REGENXBIO and its licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas. 

CONTACT:

Investors
Heather Savelle, 646-395-3734
[email protected]

Media
Laura Bagby, 312-448-8098
[email protected]